Cycloadditions and Annulations of Epimeric Pyrroloimidazolone Derivatives for the Synthesis of Novel Drug Leads

The proposed research aims to exploit specific applications of epimeric pyrroloimidazolones (EPIs) for the synthesis of new drug leads. Two classes of biologically active molecules will be targeted. First, EPIs will serves as intermediates toward chiral bicyclic[2.2.2]octenes with nitrogen at the bridgehead position, which are known to have a broad range of biological activities. Second, EPIs will be used to develop a series of dihydrofurans such as nucleoside analogues that have known utility for treatment of various cancers. This second series of molecules are related to Sapacitabine, a drug which is currently in advanced clinical trials for chronic lymphocytic leukemia and non-small cell lung cancers.

Faculty Supervisor:

Costa Metallinos

Student:

Partner:

Springboard Atlantic Inc.

Discipline:

Physics

Sector:

Pharmaceuticals; Health and Related Sciences & Technology

University:

Brock University

Program: